全球乙型肝炎评估与治疗中的性别和种族差异
该研究基于REAL-B联盟2000-2021年数据,分析9国25中心12566例初治慢性乙型肝炎患者。73.3%获充分评估,其中32.6%符合AASLD治疗标准,83.3%启动核苷(酸)类似物治疗。女性符合治疗者启动治疗可能性低约50%,西方亚洲患者评估和治疗率最低。
要点
- 女性符合治疗标准者启动核苷(酸)类似物治疗的可能性较男性低约50%(aOR 0.54)。
- 西方亚洲患者较东方亚洲患者充分评估和治疗的可能性低约40-50%。
- 总体评估率和治疗率欠佳,需语言和文化适配的关怀衔接。
核心结论
- 东西方慢性乙型肝炎患者的评估和治疗率均欠佳,存在显著性别和种族差异。
- 女性符合治疗标准者启动核苷(酸)类似物治疗的可能性低约50%。
- 西方亚洲患者较东方亚洲患者充分评估和治疗的可能性低约40-50%。
研究设计与样本
- 横断面研究,嵌套于回顾性跨国临床联盟(REAL-B,2000-2021年)。
- 纳入9国25中心12566例成人初治慢性乙型肝炎患者,平均年龄47.1岁,女性41.7%,亚洲人96.1%,西方地区49.6%,肝硬化8.7%。
主要发现
- 总体73.3%(9206例)获充分评估。
- 充分评估者中32.6%(3001例)符合AASLD治疗标准,其中83.3%(2500例)启动核苷(酸)类似物治疗。
- 女性与充分评估相关(aOR 1.13,p=0.004),但符合治疗标准的女性启动核苷(酸)类似物治疗的可能性低约50%(aOR 0.54,p<0.001)。
- 西方亚洲患者较东方亚洲患者充分评估的可能性低约40-50%(aOR 0.60,p<0.001),启动核苷(酸)类似物治疗的可能性低约40-50%(aOR 0.54,p<0.001)。
- 非亚洲患者与东方亚洲患者之间无差异。
关键数值与推荐
- 充分评估:73.3%(9206/12566例)。
- 符合AASLD治疗标准:32.6%(3001/9206例)。
- 启动核苷(酸)类似物治疗:83.3%(2500/3001例)。
- 女性启动治疗aOR 0.54(p<0.001);女性充分评估aOR 1.13(p=0.004)。
- 西方亚洲患者充分评估aOR 0.60(p<0.001),启动治疗aOR 0.54(p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Oral antiviral therapy with nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are limited. We examined rates of evaluation and treatment in patients from the REAL-B consortium. METHODS: This was a cross-sectional study nested within our retrospective multinational clinical consortium (2000-2021). We determined the proportions of patients receiving adequate evaluation, meeting AASLD treatment criteria, and initiating treatment at any time during the study period. We also identified factors associated with receiving adequate evaluation and treatment using multivariable logistic regression analyses. RESULTS: We analyzed 12,566 adult treatment-naïve patients with CHB from 25 centers in 9 countries (mean age 47.1 years, 41.7% female, 96.1% Asian, 49.6% Western region, 8.7% cirrhosis). Overall, 73.3% (9,206 patients) received adequate evaluation. Among the adequately evaluated, 32.6% (3,001 patients) were treatment eligible by AASLD criteria, 83.3% (2,500 patients) of whom were initiated on NAs, with consistent findings in analyses using EASL criteria. On multivariable logistic regression adjusting for age, sex, cirrhosis, and ethnicity plus region, female sex was associated with adequate evaluation (adjusted odds ratio [aOR] 1.13, p = 0.004), but female treatment-eligible patients were about 50% less likely to initiate NAs (aOR 0.54, p <0.001). Additionally, the lowest evaluation and treatment rates were among Asian patients from the West, but no difference was observed between non-Asian patients and Asian patients from the East. Asian patients from the West (vs. East) were about 40-50% less likely to undergo adequate evaluation (aOR 0.60) and initiate NAs (aOR 0.54) (both p <0.001). CONCLUSIONS: Evaluation and treatment rates were suboptimal for patients with CHB in both the East and West, with significant sex and ethnic disparities. Improved linkage to care with linguistically competent and culturally sensitive approaches is needed. IMPACT AND IMPLICATIONS: Significant sex and ethnic disparities exist in hepatitis B evaluation and treatment, with female treatment-eligible patients about 50% less likely to receive antiviral treatment and Asian patients from Western regions also about 50% less likely to receive adequate evaluation or treatment compared to Asians from the East (there was no significant difference between Asian patients from the East and non-Asian patients). Improved linkage to care with linguistically competent and culturally sensitive approaches is needed.
引用
- Kudaravalli S, Huang DQ, Yeh ML, et al. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world. J Hepatol. 2024. PMID: 38906621. doi:10.1016/j.jhep.2024.02.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。